Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
233 hedge funds and large institutions have $4.75B invested in Soleno Therapeutics in 2025 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 106 increasing their positions, 57 reducing their positions, and 34 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 57
50% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 34
22% more capital invested
Capital invested by funds: $3.9B → $4.75B (+$853M)
7% more funds holding
Funds holding: 217 → 233 (+16)
6.38% less ownership
Funds ownership: 118.99% → 112.61% (-6.4%)
10% less call options, than puts
Call options by funds: $163M | Put options by funds: $181M
16% less funds holding in top 10
Funds holding in top 10: 19 → 16 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$82.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$79.4M |
| 3 |
BlackRock
New York
|
+$69.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$46.5M |
| 5 |
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Warszawa,
Poland
|
+$37.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$80.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$65.4M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$61.1M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$56.6M |
| 5 |
CC
Commodore Capital
New York
|
-$40.4M |
SLNO Hedge Fund Activity: Q2 2025 in Review
233 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q2 2025, worth a combined $4.75B — up 22% from $3.9B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new SLNO positions and 34 closed out — a net gain of 17 holders — while 106 added to existing stakes and 57 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $82.7M. The largest seller was Perceptive Advisors, cutting an estimated $80.5M.
- 233 institutional investors held Soleno Therapeutics (SLNO) as of Q2 2025, up from 217 in Q1 2025.
- Funds reported $4.75B of Soleno Therapeutics stock for Q2 2025, up 22% quarter-over-quarter.
- 51 funds opened new Soleno Therapeutics positions in Q2 2025 and 34 closed out, a net change of +17 holders.
- The largest Soleno Therapeutics buyer in Q2 2025 was Fidelity Investments, an estimated $82.7M added.
- The largest Soleno Therapeutics seller in Q2 2025 was Perceptive Advisors, an estimated $80.5M sold.
Based on aggregated 13F filings for Q2 2025.